MXPA03009341A - ALCOHOLES GRASOS Y ESTERES DE ACIDOS GRASOS UTILES PARA EL TRATAMIENTO DE LA INFLAMACIoN. - Google Patents

ALCOHOLES GRASOS Y ESTERES DE ACIDOS GRASOS UTILES PARA EL TRATAMIENTO DE LA INFLAMACIoN.

Info

Publication number
MXPA03009341A
MXPA03009341A MXPA03009341A MXPA03009341A MXPA03009341A MX PA03009341 A MXPA03009341 A MX PA03009341A MX PA03009341 A MXPA03009341 A MX PA03009341A MX PA03009341 A MXPA03009341 A MX PA03009341A MX PA03009341 A MXPA03009341 A MX PA03009341A
Authority
MX
Mexico
Prior art keywords
sub
inflammation
treatment
fatty acid
acid esters
Prior art date
Application number
MXPA03009341A
Other languages
English (en)
Inventor
Irun R Cohen
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MXPA03009341A publication Critical patent/MXPA03009341A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MXPA03009341A 2001-04-11 2002-04-11 ALCOHOLES GRASOS Y ESTERES DE ACIDOS GRASOS UTILES PARA EL TRATAMIENTO DE LA INFLAMACIoN. MXPA03009341A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14253501A IL142535A0 (en) 2001-04-11 2001-04-11 Pharmaceutical compositions for the treatment of inflammation
PCT/IL2002/000294 WO2002083122A1 (en) 2001-04-11 2002-04-11 Fatty alcohols and fatty acid esters useful for treatment of inflammation

Publications (1)

Publication Number Publication Date
MXPA03009341A true MXPA03009341A (es) 2004-02-12

Family

ID=11075312

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009341A MXPA03009341A (es) 2001-04-11 2002-04-11 ALCOHOLES GRASOS Y ESTERES DE ACIDOS GRASOS UTILES PARA EL TRATAMIENTO DE LA INFLAMACIoN.

Country Status (17)

Country Link
US (1) US20060183797A1 (es)
EP (1) EP1385500B1 (es)
JP (1) JP2004525180A (es)
KR (1) KR20030096312A (es)
CN (1) CN100352433C (es)
AT (1) ATE475416T1 (es)
AU (1) AU2002255241B2 (es)
CA (1) CA2442953A1 (es)
DE (1) DE60237148D1 (es)
HU (1) HUP0303881A3 (es)
IL (1) IL142535A0 (es)
MX (1) MXPA03009341A (es)
NO (1) NO20034558L (es)
NZ (1) NZ528784A (es)
PL (1) PL366586A1 (es)
WO (1) WO2002083122A1 (es)
ZA (1) ZA200307783B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
DE60223670T2 (de) 2001-04-18 2008-03-06 Prometic Biosciences Inc., Mont-Royal Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen.
AU2003233147B2 (en) 2002-05-13 2008-03-06 Arexis Ab Autoimmune conditions and NADPH oxidase defects
NZ539106A (en) * 2002-10-10 2007-02-23 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
CN100427081C (zh) 2003-02-07 2008-10-22 普罗米蒂克生物科学公司 作为红细胞生成刺激剂的中链长脂肪酸类、甘油酯类和类似物
EP1617830A4 (en) * 2003-03-20 2008-09-24 Imagenetix Inc ESTERIFIED FATTY ACID COMPOSITION
US20050158329A1 (en) 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
KR100767701B1 (ko) * 2004-04-24 2007-10-18 김상희 모노아세틸디아실글리세롤류 화합물을 유효성분으로 함유하는 면역조절제 및 항암제
JP4954450B2 (ja) * 2004-06-14 2012-06-13 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
CN102050720B (zh) 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
WO2006123550A1 (ja) * 2005-05-16 2006-11-23 Nippon Suisan Kaisha, Ltd. 炎症性疾患予防又は治療剤
US7294739B1 (en) 2006-11-06 2007-11-13 Teva Pharmacaetical Industries Ltd. Basic amine esters or oleic acid and their use as anti-inflammatory or immunobodulatory agents
KR100787765B1 (ko) * 2006-11-07 2007-12-24 고려대학교 산학협력단 팔미트산을 포함하는 알츠하이머병의 예방 또는 치료용조성물
EP2123296B1 (en) * 2007-01-31 2019-05-22 Hisamitsu Pharmaceutical Co., Inc. Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing the same
EP2117301A4 (en) * 2007-02-26 2010-04-14 Yeda Res & Dev USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS
WO2008106092A1 (en) 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
ES2415684T3 (es) 2007-03-28 2013-07-26 Aker Biomarine As Composiciones de aceite de kril biológicamente eficaces
ES2664594T3 (es) * 2007-11-02 2018-04-20 Prometic Pharma Smt Limited Ácidos grasos de cadena media y glicéridos como agentes nefroprotectores
US9239334B2 (en) * 2008-09-08 2016-01-19 President And Fellows Of Harvard College Fatty acid C16: 1N7-palmitoleate a lipokine and biomarker for metabolic status
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
EP2272383A1 (en) * 2009-06-22 2011-01-12 SBAE Industries NV Composition Comprising Omega-7 and/or Omega-4 Fatty Acids
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
EP3064218B1 (en) 2013-10-31 2019-06-19 Hisamitsu Pharmaceutical Co., Inc. Adjuvant composition
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
KR102152850B1 (ko) * 2014-03-28 2020-09-07 주식회사 엘지생활건강 글리세린 지방산 유도체의 용도
EP3256003B1 (en) 2015-02-11 2022-11-09 Aker Biomarine Antarctic AS Lipid extraction processes
RU2718983C2 (ru) 2015-02-11 2020-04-15 Акер Биомарин Антарктик Ас Композиции липидов
AU2016219974A1 (en) * 2015-02-18 2017-09-07 Tersus Life Sciences, LLC Methods for improving joint function
CN117298092A (zh) 2016-06-08 2023-12-29 善睿圣医药保健股份有限公司 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
KR101817552B1 (ko) * 2016-10-13 2018-01-11 주식회사 엔지켐생명과학 모노아세틸디아실글리세롤 화합물을 함유하는 간염의 예방 또는 치료용 조성물
CN108853066A (zh) * 2018-09-20 2018-11-23 成都中医药大学 链式脂肪醇在制备抗炎、镇痛药物中的用途
CN112168812B (zh) * 2019-07-02 2022-07-08 瑞微(深圳)生物科技有限公司 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途
CN114544783B (zh) * 2020-11-20 2024-01-30 上海交通大学医学院附属瑞金医院 一种预防银屑病复发的内源性代谢物组合

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US612700A (en) * 1898-10-18 Disk plow
US6458772B1 (en) * 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3482551D1 (de) * 1983-10-26 1990-07-26 Kanebo Ltd Proteinhaltiges emulgiermittel, dessen herstellung und dieses enthaltende emulgierte kosmetische zusammensetzung.
CH679119A5 (es) * 1988-05-13 1991-12-31 Sandoz Ag
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5194451A (en) * 1989-11-02 1993-03-16 Katz David H Systemic anti-inflammatory treatment
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
TW355153B (en) * 1996-05-21 1999-04-01 Toshiba Machine Co Ltd A method for leveling abrasive cloth and device for the same
EP1001759B1 (en) * 1996-09-17 2005-07-20 Avanir Pharmaceuticals Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides
NZ334852A (en) * 1996-10-11 2001-05-25 Scotia Holdings Plc Use and preparation containing eicosapentaenoic acid (EPA; 20:5n-3) for treating schizophrenia
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6210700B1 (en) * 1997-01-14 2001-04-03 Novartis Nutrition Ag Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy
US6242426B1 (en) * 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
EP0919230A1 (en) * 1997-12-01 1999-06-02 Societe Des Produits Nestle S.A. NMIFA's as anti-inflammatory agents in superficial mammal tissues
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
PT1194109E (pt) * 1999-06-25 2004-12-31 Durham Pharmaceuticals Ltd Formulacoes topicas compreendendo agentes de penetracao na pele e utilizacao dasmesmas
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
NZ539106A (en) * 2002-10-10 2007-02-23 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents

Also Published As

Publication number Publication date
CA2442953A1 (en) 2002-10-24
US20060183797A1 (en) 2006-08-17
NZ528784A (en) 2007-06-29
KR20030096312A (ko) 2003-12-24
NO20034558D0 (no) 2003-10-10
JP2004525180A (ja) 2004-08-19
AU2002255241B2 (en) 2007-08-02
HUP0303881A3 (en) 2009-10-28
EP1385500A1 (en) 2004-02-04
EP1385500B1 (en) 2010-07-28
ATE475416T1 (de) 2010-08-15
DE60237148D1 (de) 2010-09-09
WO2002083122A1 (en) 2002-10-24
HUP0303881A2 (hu) 2004-03-01
ZA200307783B (en) 2004-10-06
CN100352433C (zh) 2007-12-05
NO20034558L (no) 2003-12-10
CN1514723A (zh) 2004-07-21
PL366586A1 (en) 2005-02-07
IL142535A0 (en) 2002-03-10
EP1385500A4 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
EP1385500A4 (en) FATTY ALCOHOLS AND FATTY ACID ESTERS FOR TREATING INFLAMMATION
DE60237358D1 (es)
CY1111808T1 (el) Συνθεσεις εχουσες αποτελεσματα προληψης ή βελτιωσης καταστασεων ή νοσων που προκαλουνται απο εγκεφαλικη υπολειτουργια
AU2001232786A1 (en) Process for making an enriched mixture of polyunsaturated fatty acid esters
AU2001232929A1 (en) Biodegradable oleic estolide ester having saturated fatty acid end group useful as lubricant base stock
AU1417901A (en) Process for producing fatty acid lower alcohol ester
EP1408951A4 (en) ANTI-FLAMMABILITY FATTY ALCOHOLS AND FATTY ACID ESTERS AS ANTIGENS
ZA200802678B (en) Non-hydrogenated hardstock fat
EP1504677A4 (en) TASTE EXHAUSTER CONTAINING A LONG CHAIN POLYUNSATURATED FATTY ACID AND / OR AN ESTER OF THIS FATTY ACID, AND A VEGETABLE FAT COMPOSITION COMPRISING SUCH A TASTE FISHER
AU2002311326A1 (en) Process for producing fat comprising triglyceride containing highly unsaturated fatty acid
SG149825A1 (en) Body taste improver comprising long-chain highly unsaturated fatty acid and/or ester thereof
EP1117374A4 (en) DICARBOXYLIC ACID ESTERS OF ALCOHOLIC ALCOHOLIC ALCOHOL
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
AU2002213634A1 (en) Method for the production of fatty acid esters of lower alcohols
IL144573A0 (en) Method for obtaining an oil that is rich in hydroxyoctadecadienoic fatty acids (hode) or the esters thereof from a mixture containing linoleic acid or the esters thereof
EP1435978A4 (en) ESTERS OF AROMATIC ALKOXYLATED ALCOHOLS AND FATTY ACIDS
WO2002049582A3 (de) Kosmetische und dermatologische lichtschutzformulierungen mit einem gehalt an benzotriazolderivaten und oberflächenaktiven zitronensäureestern
ATE256654T1 (de) Cla-ester
EP1795591A4 (en) LIPASE POWDER, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF
IL158226A0 (en) Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers

Legal Events

Date Code Title Description
FG Grant or registration